Flow diversion at biological maturity but clinical precision lags

An AJNR editorial argues flow diversion has reached biological maturity but not clinical maturity: priorities now shift to standardized imaging, predictive selection, surface-modified devices, and evidence-based antiplatelet regimens like the COATING trial for safer, more durabl…

• Editorial in American Journal of Neuroradiology frames the third decade of flow diversion around precision rather than broader indications.
• Distal and small-vessel applications are feasible with acceptable safety; COATING trial and F2B2 classification are highlighted as advances for antiplatelet strategy and device assessment.
• Calls for standardized imaging endpoints, predictive patient selection, and reproducible deployment techniques for predictable arterial reconstruction.

Single editorial; specific COATING trial data and F2B2 framework details are not verified from the snippet alone.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.